Table 3.

OS by ERCC1 and RRM1 Categories in the Observation and Adjuvant Chemotherapy Arms (P = 0.60, Test for Equality of the Four HRs)

	Chemotherapy group	Control group	HR for death (95% CI) (P value)
ERCC1 <10/RRM1 <10 group (n = 235)			0.72 (0.50–1.04) (P = 0.08)
No. of deaths/No. of patients	62/129	57/106
Median survival, month	56	42
2-Year survival rate, mean (range)	0.74 (0.65–0.80)	0.64 (0.55–0.73)
5-Year survival rate, mean (range)	0.47 (0.38–0.57)	0.41 (0.32–0.52)
ERCC1 <10/RRM1 <10 (n = 138)			1.04 (0.63–1.72) (P = 0.89)
No. of deaths/No. of patients	33/66	33/72
Median survival, month	56	71
2-Year survival rate	0.74 (0.63–0.83)	0.73 (0.62–0.82)
5-Year survival rate	0.46 (0.32–0.60)	0.52 (0.39–0.64)
ERCC1 <10/RRM1 ≥10 (n = 169)			0.88 (0.58–1.35) (P = 0.57)
No. of events/No. of patients	46/85	47/84
Median survival, month	40	44
2-Year survival rate, mean (range)	0.74 (0.63–0.82)	0.66 (0.56–0.76)
5-Year survival rate, mean (range)	0.39 (0.28–0.51)	0.38 (0.27–0.51)
ERCC1 ≥10/RRM1 ≥10 (n = 188)			0.99 (0.66–1.47) (P = 0.95)
No. of events/No. of patients	54/93	51/95
Median survival, month	49	46
2-Year survival rate, mean (range)	0.77 (0.68–0.85)	0.70 (0.60–0.78)
5-Year survival rate, mean (range)	0.37 (0.26–0.48)	0.36 (0.25–0.48)